Semaglutide + Placebo (semaglutide)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Jun 17, 2019 → Aug 23, 2024
NCT ID
NCT03914326About Semaglutide + Placebo (semaglutide)
Semaglutide + Placebo (semaglutide) is a phase 3 stage product being developed by Novo Nordisk for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT03914326. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04916470 | Phase 3 | Completed |
| NCT04777409 | Phase 3 | Active |
| NCT04865770 | Phase 3 | Completed |
| NCT04788511 | Phase 3 | Completed |
| NCT04251156 | Phase 3 | Completed |
| NCT04560998 | Phase 3 | Completed |
| NCT04032197 | Phase 1 | Completed |
| NCT03989232 | Phase 3 | Completed |
| NCT03987451 | Phase 2 | Completed |
| NCT03819153 | Phase 3 | Completed |
| NCT03914326 | Phase 3 | Completed |
| NCT03811561 | Phase 3 | Active |
| NCT03811574 | Phase 3 | Completed |
| NCT03574597 | Phase 3 | Completed |
| NCT03693430 | Phase 3 | Completed |
| NCT03611582 | Phase 3 | Completed |
| NCT03548935 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2